Treatment of lympho-proliferative disease with rituximab

Lancet. 2000 Feb 5;355(9202):499. doi: 10.1016/S0140-6736(00)82057-7.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • Epstein-Barr Virus Infections / drug therapy
  • Heart-Lung Transplantation
  • Herpesviridae Infections / drug therapy
  • Herpesvirus 4, Human
  • Humans
  • Lung Transplantation
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / virology
  • Male
  • Middle Aged
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / virology
  • Rituximab
  • Tumor Virus Infections / drug therapy

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab